Welcome to the Current Issues section of the International Journal of Innovations in Oncology Pharmacy Practice (IJIOPP). This space offers seamless access to all published volumes and issues, ensuring that readers, researchers, and professionals can stay up to date with the latest developments and breakthroughs in oncology pharmacy practice.
Featured Articles in the Latest Issue
- Volume 1 (Issue 2) JULY– DECEMBER 2025
Research Articles
Pharmacist-Led Oral Chemotherapy Monitoring: effect on adherence and management of toxicity in outpatient breast cancer patients
Vol.1(2); Pages:1-11. Published on July-2025
Abstract
Oral chemotherapy has revolutionized the practice of cancer treatment but has created new issues of drug adherence and adverse event management, particularly in the outpatient clinic. The research is the assessment of the effects of a pharmacist-driven monitoring program on adherence and management of toxicity in breast cancer patients who access oral chemotherapy. Eighty patients undergoing capecitabine and palbociclib were assigned to a 12-week intervention that comprised of weekly telephonic follow-ups, evaluations of side effects, and education concerning the medication. The adherence to medication was assessed with the use of the Morisky Medication Adherence Scale (MMAS-8), and the toxicity was monitored according to the CTCAE v5.0. At the end of the results, it was shown that there was statistically significant improvement in medication adherence (p < 0.01) and decrease in Grade 3 or higher toxicities. Also, patients expressed higher satisfaction with the care they received and were more supported by the health care team. These results highlight the need of increasing the role of oncology pharmacist in the management of oral chemotherapy to assure patient safety and better treatment outcomes in ambulatory cancer care.
View Full PDF
Please LOGIN to View Full PDF or Read more.
Clinical Pharmacist-Led Oral Chemotherapy Adherence Programs among Patients with Breast Cancer: A Multicentric Study
Vol.1(2); Pages:12-20. Published on July-2025
Abstract
Oral chemotherapy has brought a very positive shift in treating cancer; enabling home based treatment, however there are major issues of adherence and managing toxicity. The study was a multicentered, interventional research study to understand how therapeutic treatment adherence programs discussed by clinical pharmacists in three oncology centers in Switzerland, India, and South Africa yielded. One hundred and forty breast cancer patients with oral chemotherapy (capecitabine or palbociclib) were provided structured counseling with follow-ups every two weeks and the monitoring of adverse events during the 12 weeks. Toxicity and hospitalization data were used to measure clinical outcomes of safety, whereas the MMAS-8 scale and pharmacy refill reports were used to evaluate adherence. The outcomes were 22%-enhanced adherence scores (p < 0.001), less rare adverse events (Grade 3 or more ride), and improved patient satisfaction, with 87% of participants claiming that pharmacist assistance is an essential part of their treatment. Results highlight the importance of pharmacist-led interventions in safely, effectively and patient-centering oral chemotherapy management.
View Full PDF
Please LOGIN to View Full PDF or Read more.
An in vivo survey of using pharmacist-led antiemetic stewardship to get rid of chemotherapy-induced nausea and vomiting
Vol.1(2); Pages:21-30. Published on July-2025
Abstract
Chemotherapy induced nausea and vomiting (CINV) affect strongly the patient adherence, the success of treatments, and patient quality of life. This observational study in the real world evaluated the effectiveness of the pharmacist-administered antiemetic stewardship programs in three hospitals in the country of Sweden, Egypt, and the UAE. The intervention consisted of pharmacist-led choice of antiemetic regimen in accordance with international guidelines, pre-treatment education of patients and active monitoring of breakthrough CINV. There were 210 cancer patients undergoing highly emetogenic chemotherapeutic agent like cisplatin and doxorubicin, and each patient underwent four cycles. Investigated outcomes showed a 28 percent improved complete response, that is, no nausea, no vomiting and the absence of rescue medication, versus base (p
View Full PDF
Please LOGIN to View Full PDF or Read more.
Outcomes with fluoropyrimidine chemotherapy: Pharmacogenomic Guided Dosing in Colorectal Cancer
Vol.1(2); Pages:31-39. Published on August-2025
Abstract
Pharmacogenomic-based dosing allows fluoropyrimidines therapy of colorectal cancer to be used safely and more effectively due to consideration of individual genetic variation. Our study was a prospective clinical trial that recruited 120 patients in oncology centers in Italy and Japan to compare pre-treatment DPYD and TYMS genotype to improve clinical utility of genotyping in the pre-treatment setting. Patients were dosed with fluoropyrimidine-based chemotherapy presumptively adjusted to their pharmacogenomic profile whereas outcomes were compared to a historical control group with matched pharmacogenomic dosing. The pharmacogenomic-guided cohort reported 32 percent fewer Grade 34 toxicities ( p < 0.001) than patients with a typical algorithm and increased adherence to their regimen together with a small, but statistically significant progression-free survival advantage. There was also a much higher satisfaction rating of personalized therapy as reported by the patient. This study justifies the standard implementation of pharmacogenomic screening in treatment plans, where colorectal cancer is concerned, in order to promote safety and increase efficacy of treatment.
View Full PDF
Please LOGIN to View Full PDF or Read more.
Analysis of clinical pharmacist intervention in minimizing drug-drug interactions of patients on targeted oral oncology drugs
Vol.1(2); Pages:40-50. Published on August-2025
Abstract
Drug-drug interactions (DDIs) are a considerable challenge in the context of the use of targeted oral anticancer therapies, such as tyrosine kinase inhibitors (TKIs) and CDK4/6 inhibitors, since their metabolism is complex and polypharmacy is taken. The objective of the proposed study was to conduct a prospective observational study using an intervention implemented by clinical pharmacists to help in the reduction of DDIs in 185 patients in two tertiary cancer patients in Germany and Brazil. Carefully performed medication reviews, the degree of interaction between medications was established with the assistance of Lexicomp 1 and Micromedex 1, and recommendations addressed to oncologists were offered by pharmacists. They were identified 312 potential DDIs (clinically significant in 76 percent of cases). Therapy was reduced or changed in accordance with interventions in 71 percent of the cases or doses were changed. Subsequent care reported 40 percent less adverse drug events caused by the interactions and thereby increasing patient safety and treatment compliance.
View Full PDF
Please LOGIN to View Full PDF or Read more.
Accessing the Articles
You can access the full text of these articles by clicking on the titles or visiting our journal’s online archives.
Stay Updated
To stay informed about the latest research and updates in the journal, consider subscribing to our newsletter or following us on social media.
